Table 5.
Early Phase II studies with bevacizumab in ovarian cancer
| Study | Regimen | Patients | Population | ORR | Duration of response (median) | PFS > 6 months |
|---|---|---|---|---|---|---|
| Burger et al37 | Bev 15 mg/kg q3wk | 62 | 1–2 prior regimens; | 21% | 10.3 months | 25 pt |
| GOG I70D | platinum-sensitive (42%) | 90% CI: | Median PFS | 40.3% | ||
| and resistant (58%) | 12.9%–31.3% | 4.7 months | 90% CI: 29.8%-53.6% | |||
| Median OS 17 months | ||||||
| Garcia et al38 | Bev | 70 | Plat sens (60%) and | PR 24% | 56% | |
| metronomic | resistant (40%) | 95% CI: | SE-GI fistula in 4 | 95% CI: 44%–67% | ||
| cyclophosphamide | 15%–36% | PFS platinum-sensitive = 8 months | ||||
| versus platinum-resistant = 5 months | ||||||
| P = 0.004 | ||||||
| Cannistra et al35 | Bev | 44 | Platinum-refractory or | 15.9% | 27.8% | |
| resistant | 95% CI: | SE-GI perf 11.4%; 5/44 | PFS median 4 months | |||
| 2-3 prior regimens | 7.2%–29% | OS median 11 months |
Abbreviations: Bev, bevacizumab; CI, confidence interval; ORR, Overall Response Rate; PFS, progression-free survival; SE, side effects; Gl, gastro intestinal; pt, every 3 weeks.